Evaluation of Minimal Residual Disease (MRD) in Children with B-Cell Acute Lymphoblastic Leukemia During Maintenance of Remission

  • J. Peregud-Pogorzelski
  • J. Lubinski
  • A. Brodkiewicz
  • A. Jakubowska
  • V. Swiatkiewicz
  • A. Kurylak
Conference paper
Part of the Haematology and Blood Transfusion Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 41)

Abstract

Application of molecular biology techniques in investigations of acute lymphoblastic leukemia contributed to better understanding of leukemic transformation mechanisms and allowed more accurate evaluation of treatment efficacy. The idea of residual malignant cells (MRD) has been introduced in order to evaluate more accurately the real number of circulating leukemic cells and to improve the methods of treatment and survival rates [7]. Monoclonal rearrangements of IgH and TCR genes are unique features of the given leukemic clone which allows monitoring of minimal residual disease (MRD) using the method of polymerase chain reaction (PCR). The rearrangements of IgH gene may be used in monitoring of residual leukemic cells in most cases of B-cell acute lymphoblastic leukemia. Majority of MRD studies in ALL were performed exclusively in children [1, 3, 4, 5, 9, 12, 13, 15, 17, 18, 19, 21, 22]. Elimination of residual leukemic cells confirmed by negative results of PCR test may predict long -term event- free survivals [14]. Many reports underline that positive PCR result frequently predicts relapse; however, it should be emphasized, that the result depends mainly on frequency and timing of the studies. The positive PCR results are also associated mainly with the medullary relapse [9,12,15, 17,18,19,22]. It is suggested that quantitative evaluation of MRD is more important than positive result found in a single investigation [16,17]. Some authors believe that evaluation of MRD at the end of the treatment constitute a valuable test for identifying patients likely to relapse [5,6, 13,18]. Other authors underline the lack of predictive value of that test in every single time point, thus indicating the need for serial semi — quantitative studies [16,17].

Keywords

Phenol Agar Lymphoma Leukemia Bromide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Biondi A, Yokota T, Hansen-Hagge T, Rosii V, Giudici G, Maglia O, BasooG, Tell C, Masera G, Bartram CR (1992) Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse. Leukemia 6: 282–288PubMedGoogle Scholar
  2. 2.
    Bradstock KF, Gottlieb DJ (1995) Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease. Leuk Lymphoma 18: 1–16.PubMedCrossRefGoogle Scholar
  3. 3.
    Brisco M, Condon J, Sykes P, Neoh SH, Morley AA (1991) Detection and quantification of neoplastic cells in acute lymphoblastic leukemia by use of polymerase chain reaction. Br J Haematol 79: 21–217CrossRefGoogle Scholar
  4. 4.
    Brisco MJ, CondonJ, Hughes E, Neoh SH, Nicholson I, Sykes P, Yauro J, Ekhert H, Waters K, Toogood I, Sehardi R, Morley A (1993) Prognostic significance of detection of monoclonality in remission marrow in acute lymphoblastic leukemia in childhood. Leukemia 7: 1514–1520.PubMedGoogle Scholar
  5. 5.
    Brisco M, Condon J, Highes E, Neoh S, Sykes P, Seshardi R, Toogood I, Waters K, Tauro G, Ekert H, & Morley A (1994) Outcome prediction in childhood acute lymphoblastic leukemia by molecular quantification of residual disease at the end of induction. Lancet 343: 196–200PubMedCrossRefGoogle Scholar
  6. 6.
    Brisco MJ, Hughes E, Neoh SH, Sykes PJ, Bradstock K, Enno A, Szer J, McCaul K, Morley AA (1996) Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood 87: 5251–5256PubMedGoogle Scholar
  7. 7.
    Campana D, Pui CH (1995) Detection of minimal residual disease in acute lymphoblastic leukemia: methodologic advances and clinical significance. Blood 85: 1416–1434.PubMedGoogle Scholar
  8. 8.
    Estrov Z, Grunberger T, Dube ID, Wang YP, Freedman MH (1986) Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. N Engl J Med 315: 538–542PubMedCrossRefGoogle Scholar
  9. 9.
    Foroni L, Coyle LA, Papaionnou M, Yaxley JC, Cole Sinclair MF, Chim JS, Cannell P, Seeker-Walker LM, Mehta AB, Prentice HG, and Hoffbrand AV (1997) Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukemia reveals differences in treatment response. Leukemia 11: 1732–1741PubMedCrossRefGoogle Scholar
  10. 10.
    Gale RP, Butturini A (1991) Maintenance chemotherapy and cure of childhood acute lymphoblastic leukemia. Lancet 338: 1315–1318PubMedCrossRefGoogle Scholar
  11. 11.
    George SL, Aur RIA, Mauer AM, Simone JV (1979) A reappraisal of the results of stopping therapy in childhood leukemia. N Engl J Med. 300: 269–273PubMedCrossRefGoogle Scholar
  12. 12.
    Gruhn B, Hongeng HY, Hancock ML, Rubnitz JE, Neale CAM, and Kitchingman CR (1998) Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia 12: 6765–681CrossRefGoogle Scholar
  13. 13.
    Ito Y, Wasserman R, Galili N, Reichard BA, Shane S, Lange B, Rovera G (1993) Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with acute lymphoblastic leukemia. J Clin Oncol 11: 546–553PubMedGoogle Scholar
  14. 14.
    Ito Y, Miyamure K (1994) Clinical significance of minimal residual disease in leukemia detected by polymerase chain reaction: is molecular remission a milestone for achieving a cure? Leuk Lymphoma 16: 57–64PubMedCrossRefGoogle Scholar
  15. 15.
    Kitchingman GR (1994) Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukemia. Leukemia 8: 395–401PubMedGoogle Scholar
  16. 16.
    Nizet Y, Martiat P, Vaerman JL, Philippe M, Widmann C, Staelens JP, Cornu G, Ferrant A, Michaux JL, Sokal G (1991) Follow-up of residual disease (MRD) in B lineage acute leukemias using a simplified PCR strategy: evolution of MRD rather than detections is correlated with clinical outcome. Br J Haematol 79: 205–210PubMedCrossRefGoogle Scholar
  17. 17.
    Nizet Y, VanDaele S, Lewalle P, Vaerman JL, Philippe M.,Vermylen C, Comu G, Ferrant A, Michaux JL, Martiat P. (1993) Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogenic IgH probes and the polymerase chain reaction. Blood 3 (82): 1618–1625Google Scholar
  18. 18.
    Potter MN, Steward CG, Oakhill A (1993) The sig¬nificance of detection of minimal residual disease in childhood acute lymphoblastic leukemia. Br J Haematol 83: 412–418PubMedCrossRefGoogle Scholar
  19. 19.
    Roberts WM, Estrow Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF (1997) Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia N Engl J Med 336: 317–323Google Scholar
  20. 20.
    Wan JH, Trainor KJ, Brisco MJ, Morley AA (1990) Monoclonality in B cell Lymphoma detected in paraffin wax embedded sections using the poly¬merase chain reaction J Clin Pathol 43: 888–890PubMedCrossRefGoogle Scholar
  21. 21.
    Wasserman R, Galili N, Ito Y, Silber J, Reichard B, Shane S, Womer RB, Lange B, Rovera G (1992) Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol 10: 1879–1888PubMedGoogle Scholar
  22. 22.
    Yamada M, Wasserman R, Lange B, Reichard BA, Womer RB, Rivera G (1990) Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemia cells during the first 18 months of treatment. N Engl J Med 323: 448–455PubMedCrossRefGoogle Scholar
  23. 23.
    Yokota S, Hansen-Hagge TE, Ludwig WB, Reiter A, Raghavachar A, Kleihauer E, Bartram CR (1991) Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 77: 331–339PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • J. Peregud-Pogorzelski
    • 1
  • J. Lubinski
    • 1
  • A. Brodkiewicz
    • 1
  • A. Jakubowska
    • 1
  • V. Swiatkiewicz
    • 2
  • A. Kurylak
    • 2
  1. 1.Department of Paediatrics, Department of Genetics and PathomorphologyPomeranian Academy of MedicineSzczecinPoland
  2. 2.Department of Paediatrics, Haematology and OncologyMedical UniversityBydgoszczPoland

Personalised recommendations